MoonLake Immunotherapeutics
Moat Score — MoonLake Immunotherapeutics
Total Moat Score
5 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 3 / 5 | MoonLake's licensed patent family on sonelokimab runs to roughly 2032, with two company-owned families pending through 2043-2044, giving it real IP protection, though the core Nanobody technology itself is licensed from Merck Healthcare KGaA rather than wholly owned. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 0 / 5 | As a pre-revenue, outsourced-manufacturing clinical-stage company with large milestone and royalty obligations to its licensor, MoonLake has no cost advantage versus larger, internally-manufacturing biopharma competitors. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 0 / 5 | With no approved products, MoonLake has no current pricing power; any future pricing will be set against entrenched, widely-reimbursed biologics like adalimumab and secukinumab. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 0 / 5 | There is no network effect in biopharmaceutical drug development or sales. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 1 / 5 | If approved, sonelokimab would face low switching costs from patients and prescribers already established on competing IL-17 and IL-23 inhibitors, though a differentiated efficacy or dosing profile could create some prescriber inertia in its favor over time. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 1 / 5 | MoonLake is a single-asset company with no commercial infrastructure yet; it has no scale advantage and would need to build or partner for commercial reach against far larger, multi-product pharmaceutical competitors. |